Investing.com - Biomarin Pharma reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Biomarin Pharma announced earnings per share of $-0.04 on revenue of $505.30. Analysts polled by Investing.com EPS of $-0.02 on revenue of $516.56M.
Biomarin Pharma 's are down 4.3% and is trading at $89.78 , still down 5.79% from its 52 week high of $97.76 set on Monday, August 8, 2022.
Biomarin Pharma shares lost 2.52% to trade at $89.78 in after-hours trade the report.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.9B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar